Clinical Report: Hematological Disorders in Patients with NASH in Qatar

Overview

Revise to specify the clinical implications of the association between hematological abnormalities and fibrosis scores.

Background

Non-alcoholic steatohepatitis (NASH) is a growing public health concern, particularly in regions like the Middle East where its prevalence is high. Understanding hematological abnormalities in NASH patients is crucial, as they may indicate systemic complications and advanced liver disease. This study aims to fill gaps in knowledge regarding the prevalence and implications of these abnormalities in a clinical setting.

Data Highlights

Key Findings

• NASH patients exhibited a higher prevalence of any CBC abnormality (35.8%) compared to controls (28.4%).
• Thrombocytopenia was significantly more frequent in NASH patients (15.4% vs. 2.5%).
• Older age, female sex, and diabetes were associated with higher rates of anemia and neutropenia in NASH patients.
• Higher FIB-4 scores correlated with increased odds of anemia and abnormal platelets.
• Routine CBC assessments may help identify NASH patients at risk for advanced liver disease.

Clinical Implications

Healthcare providers should consider routine complete blood count assessments in patients with NASH to identify hematological abnormalities that may indicate advanced liver disease. Recognizing these abnormalities can facilitate early intervention and management strategies in primary care settings.

Conclusion

Hematological disorders are prevalent in patients with NASH and may serve as important indicators of disease severity and fibrosis risk. Further research is warranted to explore the clinical significance of these findings.

Related Resources & Content

1. Journal of Gastroenterology, 2013 -- Metabolomic Analysis of Serum and Identification of Potential Biomarkers for Fibrosis Severity in Nonalcoholic Fatty Liver Disease
2. The New Gastroenterologist, 2026 -- Heavy drinking tied to increased fibrosis risk in MASLD
3. The New Gastroenterologist, 2025 -- Addressing NAFLD: Strategies to Alleviate the Effects of Nonalcoholic Fatty Liver Disease
4. Open Forum Infectious Diseases -- Assessment of Liver Fibrosis Prevalence and Associated Risk Factors in Individuals with HIV and Metabolic Dysfunction-Related Steatotic Liver Disease
5. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary - PMC
6. Platelet Thromboxane B2 overproduction associated with liver fibrosis severity in patients with MASLD - ScienceDirect
7. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary - PMC
8. Platelet Thromboxane B2 overproduction associated with liver fibrosis severity in patients with MASLD - ScienceDirect
9. A Phase 3, Randomized, Controlled Trial of... : New England Journal of Medicine